Medicaid Coverage and Utilization for Novel Therapies for Chronic Rhinosinusitis With Nasal Polyposis

International Forum of Allergy & Rhinology 2026 Open access

Read full text
Authors: Eric R. Ramos, Sriram Satyavolu, Ashley L. Miller, George A. Scangas, Zachary M. Soler, R. Schlosser, Yufan Lin, Vinay K. Rathi
DOI: 10.1002/alr.70109
Cited by: 2
References: 9

Abstract

KEY POINTS: Most state Medicaid programs granted omalizumab (91.4%) and dupilumab (59.5%) preferred drug status. Omalizumab was the most commonly prescribed therapy among Medicaid patients between 2015 and2024.

Fields of Study & Subjects

Sinusitis and nasal conditions Spondyloarthritis Studies and Treatments Allergic Rhinitis and Sensitization

Publication details

Journal / source
International Forum of Allergy & Rhinology
Publisher
Wiley
Volume
16
Issue
3
Pages
301–304
Publication date
22 January 2026
Language
EN